The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma

SRSF10介导的包含外显子10的SREK1异常上调在人类肝细胞癌中发挥致癌驱动作用。

阅读:5
作者:Cunjie Chang # ,Muthukumar Rajasekaran # ,Yiting Qiao # ,Heng Dong # ,Yu Wang ,Hongping Xia ,Amudha Deivasigamani ,Minjie Wu ,Karthik Sekar ,Hengjun Gao ,Mengqing Sun ,Yuqin Niu ,Qian Li ,Lin Tao ,Zhen Yan ,Menglan Wang ,Shasha Chen ,Shujuan Zhao ,Dajing Chen ,Lina Li ,Fan Yang ,Haojin Gao ,Baodong Chen ,Ling Su ,Liang Xu ,Ye Chen ,Veerabrahma Pratap Seshachalam ,Gongxing Chen ,Jayantha Gunaratne ,Wanjin Hong ,Junping Shi ,Gongying Chen ,David S Grierson ,Benoit Chabot ,Tian Xie ,Kam Man Hui ,Jianxiang Chen

Abstract

Deregulation of alternative splicing is implicated as a relevant source of molecular heterogeneity in cancer. However, the targets and intrinsic mechanisms of splicing in hepatocarcinogenesis are largely unknown. Here, we report a functional impact of a Splicing Regulatory Glutamine/Lysine-Rich Protein 1 (SREK1) variant and its regulator, Serine/arginine-rich splicing factor 10 (SRSF10). HCC patients with poor prognosis express higher levels of exon 10-inclusive SREK1 (SREK1L). SREK1L can sustain BLOC1S5-TXNDC5 (B-T) expression, a targeted gene of nonsense-mediated mRNA decay through inhibiting exon-exon junction complex binding with B-T to exert its oncogenic role. B-T plays its competing endogenous RNA role by inhibiting miR-30c-5p and miR-30e-5p, and further promoting the expression of downstream oncogenic targets SRSF10 and TXNDC5. Interestingly, SRSF10 can act as a splicing regulator for SREK1L to promote hepatocarcinogenesis via the formation of a SRSF10-associated complex. In summary, we demonstrate a SRSF10/SREK1L/B-T signalling loop to accelerate the hepatocarcinogenesis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。